However, resistance to first- or second-generation EGFR-TKIs frequently developed due to the acquired T790M mutation, which occurs in approximately 50%–60% of NSCLC patients treating with first- or second-generation EGFR-TKIs (Westover et al., 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.